Recent Finacing
Recent Raise
Immunservice develops IL‑2–based biological immunotherapies, producing pharmaceutical‑grade Interleukin‑2 and advancing therapies that activate patients' immune systems against renal cancer, melanoma, and viral infections.
Focus Areas
Recent Investors
Funding round
Investors
